|
TST+ subjects with a past MTB exposure: trends of RD1 test during follow up in the responders* |
||||||
| Group of subjects analysed |
Number of subjects N (%) |
Time 1 0 months |
Time 2 1–2 months |
Time 3 6 months |
Time 2 vs. time 1 |
Time 3 vs. time 1 |
|
|
||||||
| IFN-gamma (IU/ml) |
||||||
|
|
||||||
| No INH |
5 (100) |
|||||
| PHA |
5 (100) |
14.2 ± 3.4 |
17.1 ± 4.5 |
17.5 ± 4.6 |
Ns |
Ns |
| PPD |
5 (100) |
31.4 ± 2.5 |
33 ± 3.4 |
29.3 ± 4.5 |
Ns |
Ns |
| QTF-G |
5 (100) |
16.4 ± 5.1 |
12.3 ± 4.4 |
16.3 ± 6.7 |
Ns |
Ns |
| RD1 proteins |
5 (100) |
11.8 ± 3.8 |
8.9 ± 3.2 |
13.5 ± 6.1 |
Ns |
Ns |
| RD1 peptides |
5 (100) |
6.1 ± 2 |
2.2 ± 0.5 |
4.6 ± 2 |
Ns |
Ns |
| INH therapy |
9 (100) |
|||||
| PHA |
9 (100) |
17.7 ± 6 |
20.4 ± 4.4 |
17.8 ± 4.1 |
Ns |
Ns |
| PPD |
9 (100) |
19.6 ± 4.5 |
19.4 ± 4.7 |
24.2 ± 5.2 |
Ns |
Ns |
| QTF-G |
9 (100) |
15.2 ± 4 |
11.3 ± 4 |
9.4 ± 2.7 |
Ns |
Ns |
| RD1 proteins |
9 (100) |
6 ± 2 |
8.8 ± 3.3 |
11.9 ± 5.2 |
Ns |
Ns |
| RD1 peptides |
6 (66) |
4.4 ± 2.7 |
4.1 ± 1.4 |
7 ± 3 |
Ns |
Ns |
|
*Responders are defined as those responding to the tests at baseline. T1: time 1 (baseline); T2. time 2 (after 1–2 months INH therapy), T3: time 3 (after 6 months, at therapy completion). IFN: interferon; PHA: Phytohemagglutinin; PPD: purified protein derivative; RD: region of difference; QTF-G: QuantiFERON TB Gold; IFN: interferon; IU: international units. INH: isoniazid; ns: not statistically significant. | ||||||
Goletti et al. Respiratory Research 2007 8:5 doi:10.1186/1465-9921-8-5 |
||||||